[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588096":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":118,"collaborators":31,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":31,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":31,"enrollmentInfo":129,"targetDuration":31,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":31,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ONO-4538","EXPERIMENTAL","ONO-4538 480 mg solution administered intravenously every 4 weeks",[13],"Drug: ONO-4538",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","every 4 weeks",[9],[20,21],"Nivolumab","Opdivo",[23],{"name":24,"affiliation":5,"role":25},"Project Leader","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)",null,"clinical_trial@ono-pharma.com",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":32},"International Clinical Trial Support Desk","+17162141777(Standard)",[37,50,59,67,77,85,94,102,111,115],{"facility":38,"status":39,"city":40,"state":41,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":31},"Aichi Cancer Center","RECRUITING","Nagoya","Aichi-ken","Japan","JP",{"type":45,"coordinates":46},"Point",[47,48],136.90641,35.18147,{"lat":48,"lon":47},{"facility":51,"status":39,"city":52,"state":52,"zip":53,"country":42,"countryCode":43,"cosmosGeoPoint":54,"geoPoint":58,"contacts":31},"Kyusyu University Hospital","Fukuoka","812-8582",{"type":45,"coordinates":55},[56,57],130.41667,33.6,{"lat":57,"lon":56},{"facility":60,"status":39,"city":61,"state":61,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":31},"Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital","Hiroshima",{"type":45,"coordinates":63},[64,65],132.45,34.4,{"lat":65,"lon":64},{"facility":68,"status":39,"city":69,"state":70,"zip":71,"country":42,"countryCode":43,"cosmosGeoPoint":72,"geoPoint":76,"contacts":31},"Hokkaido University Hospital","Sapporo","Hokkaido","060-8648",{"type":45,"coordinates":73},[74,75],141.35,43.06667,{"lat":75,"lon":74},{"facility":78,"status":39,"city":79,"state":79,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":80,"geoPoint":84,"contacts":31},"Kyoto University Hospital","Kyoto",{"type":45,"coordinates":81},[82,83],135.75385,35.02107,{"lat":83,"lon":82},{"facility":86,"status":39,"city":87,"state":88,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":89,"geoPoint":93,"contacts":31},"Tohoku University Hospital","Sendai","Miyagi",{"type":45,"coordinates":90},[91,92],140.86667,38.26667,{"lat":92,"lon":91},{"facility":95,"status":39,"city":96,"state":96,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":97,"geoPoint":101,"contacts":31},"Niigata University Medical & Dental Hospital","Niigata",{"type":45,"coordinates":98},[99,100],139.04125,37.92259,{"lat":100,"lon":99},{"facility":103,"status":39,"city":104,"state":105,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":106,"geoPoint":110,"contacts":31},"Kindai University Hospital","Ōsaka-sayama","Osaka",{"type":45,"coordinates":107},[108,109],135.55069,34.49524,{"lat":109,"lon":108},{"facility":112,"status":39,"city":113,"state":114,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital","Bunkyō-Ku","Tokyo",{"facility":116,"status":39,"city":117,"state":114,"zip":31,"country":42,"countryCode":43,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"National Cancer Center Hospital","Chuo Ku",{"type":119,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100588096","phase-2-ono-4538-study-in-patients-with-richters-transformation-100588096",false,"NCT06936943","ONO-4538 Study in Patients With Richter's Transformation","A Multicenter, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of ONO-4538 in Patients With Richter's Transformation","Inclusion Criteria:\n\n* Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\n* In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL\n* Patients with measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Expected to survive for 90 days or more\n\nExclusion Criteria:\n\n* Serious complications\n* Active multiple cancers\n* Active central nervous system (CNS) disease\n* History of allogeneic hematopoietic stem cell transplantation","ALL","18 Years",{"count":130,"type":131},14,"ESTIMATED","INTERVENTIONAL",[134],"PHASE2","Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation",[137],"Richter's Transformation","2026-02-12",{"date":140,"type":141},"2026-02-13","ACTUAL",{"date":143,"type":141},"2025-11-19",{"date":145,"type":131},"2030-07-31",{"name":5,"class":6},10]